The WuXi Biologics, Eli Lilly and Alexandria Real Estate Equities-backed cancer therapy developer is targeting $74.7m in its IPO.

US-based biologic drug developer Inhibrx has filed for a $74.7m initial public offering that will enable pharmaceutical development services provider WuXi Biologics and pharmaceutical firm Eli Lilly to exit. Previously known as Tenium Therapeutics, Inhibrx has created a protein engineering platform it is using to develop treatments for diseases including cancer. The company will use…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.